India’s Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
Topstory
US Proposal Could Halve Biocon’s Biosimilar Development Costs
by aweeincm1
Recent Post
Gujarat Man Gets Friend To Shoot Forest Officer Wife Over Dispute
A man allegedly took the help of a friend in ... Read more
Schools To Function In Hybrid Mode Till Class 5 In Gurugram Due To Pollution
In view of deteriorating air quality in Delhi-NCR, the Gurugram ... Read more
India Seeks Russia’s Nod for Marine, Pharma Exports to Boost Trade
India has asked Russia to facilitate expedited listing of domestic ... Read more
Congress Has Become More Leftist To Counter BJP: Shashi Tharoor
Congress MP Shashi Tharoor on Thursday said the party has ... Read more